Caremark rejects Express Scripts offer
Caremark said that the proposal from Express Scripts risks losing customers and includes questionable assumptions with regard to synergies. The company also asserted that the offer is a
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) from Pfizer and Valneva for their Lyme disease vaccine candidate, PF-07307405.